Use of sulfanegen and its analogs for prevention and treatment for neurodegenerative disorders
A 3-mercaptopyruvate prodrug, sulfanegen, that reduces neuroinflammation and oxidative stress for therapeutic use in neurodegenerative diseases.
- Alzheimer’s Disease
- Parkinson's Disease
- Huntington's Disease
- Cognitive Impairment
- Non-Alcoholic Fatty Liver Disease/Non-alcoholic steatohepatitis (NAFLD/NASH)
- Tylenol (acetaminophen) toxicity
Sulfanegen is a prodrug of 3-mercaptopyruvic acid. Sulfanegen was studied for potential therapeutic benefit in Alzheimer's mouse models. In mice, sulfanegen at both doses 50 and 100 mg/kg showed a marked improvement in Alzheimer’s pathology and cognitive behavior pattern as determined by the T-maze spontaneous alternation.
Phase of DevelopmentTRL: 3-4
In vitro neuroprotection studies and in vivo studies with biochemical and T-maze cognitive assessment tests have been conducted for sulfanegen. The researchers are currently evaluating the brain tissues of these mice for detailed mechanistic understanding of sulfanegen's neuroprotective action.
Desired PartnershipsThis technology is now available for:
- Sponsored research
Please contact our office to share your business’ needs and learn more.
- More SS, Beach JM, McClelland C, Mokhtarzadeh A, Vince R. (2019), In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease
- Patterson SE, Moeller B, Nagasawa HT, Vince R, Crankshaw DL, Briggs J, Stutelberg MW, Vinnakota CV, Logue BA (2011), Development of sulfanegen for mass cyanide casualties.
- Patterson SE, Monteil AR, Cohen JF, Crankshaw DL, Vince R, Nagasawa HT (2013), Cyanide antidotes for mass casualties: water-soluble salts of the dithiane (sulfanegen) from 3- mercaptopyruvate for intramuscular administration
swap_vertical_circlecloud_downloadDownloads (0)Files marked with an asterix (*) can only be downloaded by users that have the appropriate product licence. The licence must be active and you must be logged into your account.